Does nebivolol prevent contrast-induced nephropathy in humans Full Text
Clinical Cardiology,  Clinical Article

Gunebakmaz O et al. – Pretreatment with nebivolol is protective against nephrotoxic effects of contrast media.

Methods
  • The present study enrolled 120 patients scheduled for coronary angiography and ventriculography.
  • All patients were hydrated with intravenous isotonic saline.
  • The patients in group I received 600 mg N–acetylcysteine every 12 hours for 4 days.
  • The patients in group II received 5 mg nebivolol every 24 hours for 4 days.
  • The patients in group III were only hydrated.
  • The primary endpoint was the occurrence of CIN.
  • The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure.

Results
  • Nine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III (P = 0.72).
  • Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups.
  • However, authors detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively).
  • Although an increase was detected in mean Cr level from baseline to the 5–day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close